The acquisition allows Bayer HealthCare to strengthen its Medrad Interventional business by expanding its presence in the field of vascular intervention technologies.

Pathway develops Jetstream devices which restore circulation in the peripheral arteries by removing both hard and soft diseased tissue in the leg and reduce vascular narrowing caused by plaque, thus treating peripheral arterial disease (PAD).

Bayer HealthCare Board of Management chairman Jorg Reinhardt said Pathway’s products complement Medrad Interventional’s portfolio including injectors, thrombectomy devices and the Cotavance paclitaxel coated balloon catheter with Paccocath technology and will enable them to extend value to customers and patients through broader product options to diagnose and treat PAD.